‌

US Patent 11286264 Macrocyclic compounds and uses thereof

Patent 11286264 was granted and assigned to Turning Point Therapeutics on March, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

Turning Point Therapeutics

0

Current Assignee

Turning Point Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Wei Deng0

Zhongdong Huang0

Jing Liu0

Jingrong Jean Cui0

Xin Zhang0

Dayong Zhai0

Evan W. Rogers0

Han Zhang0

...

Date of Patent

March 29, 2022

0

Patent Application Number

166342890

Date Filed

July 26, 2018

0

Patent Citations

US Patent 10294242 Diaryl macrocycle polymorph

US Patent 10246466 Diaryl macrocycles as modulators of protein kinases

0

US Patent 10316044 Chiral diaryl macrocycles as modulators of protein kinases

0

Patent Citations Received

US Patent 11981684 Macrocyclic compounds and uses thereof

0

US Patent 11945785 Pyrazine compounds as inhibitors of FLT3

0

Patent Primary Examiner

Daniel R Carcanague

0

CPC Code

0

0

0

0

The present disclosure relates to certain macrocyclic compounds that inhibit SRC and MET, and/or CSF1R, pharmaceutical compositions containing such compounds, and methods of using such compounds to treat cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11286264 Macrocyclic compounds and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool